Mercalis and PharmaCord Finalize Merger, Rebrand as Valeris

Permira Makes Substantial Growth Investment in PharmaCord

June 6, 2024

Healthcare Services

Permira (via a company backed by Permira funds) has signed a definitive agreement to make a substantial growth investment in PharmaCord, a Jeffersonville, Indiana-based tech-enabled patient services provider for specialty pharmaceuticals. Founder and CEO Nitin Sahney and the management team will remain significant investors and operators; terms were not disclosed and the deal is expected to close by Q4 2024.

Mercalis (formerly TrialCard) Acquires Triangle Insights Group

April 12, 2022

Healthcare Services

Mercalis (formerly TrialCard) acquired Triangle Insights Group, a Durham-based life sciences strategy consulting firm, to expand its commercialization capabilities. The transaction is an add-on to the Mercalis platform (which is backed by Odyssey Investment Partners) and will retain all TIG partners and employees as Mercalis integrates strategic insights, pricing and market access expertise into its full-service commercialization offering.

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

Transocean to Acquire Valaris in $5.8 Billion All-Stock Deal

February 9, 2026

Energy

Transocean and Valaris have signed a definitive agreement to combine in an all-stock transaction valued at approximately $5.8 billion, with Transocean acquiring Valaris. The deal is structured as a court-approved scheme of arrangement under Bermuda law and is expected to close in the second half of 2026, subject to regulatory and shareholder approvals.

AmerisourceBergen Acquires PharmaLex for €1.28 Billion

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation signed a definitive agreement to acquire PharmaLex Holding GmbH for €1.28 billion in cash. The deal is intended to expand AmerisourceBergen’s global biopharma services platform by adding PharmaLex’s tech-enabled, regulatory-focused life sciences expertise.

MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader

July 8, 2024

Pharmaceuticals

MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.